Lake Street analyst Thomas Flaten lowered the firm’s price target on Better Therapeutics to $3 from $5 and keeps a Buy rating on the shares after Better reported Q2 results. The firm sees the reality of Better’s markets “coming into sharper focus” as the company “moves steadily closer to commercialization of AspyreRx,” but lowered its price target to reflect updated revenue estimates and dilution from the recent financing, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTTX:
- Better Therapeutics files to sell 479,516 shares of common stock for holders
- Better Therapeutics reports Q2 EPS (24c), consensus (31c)
- Better Therapeutics issues $6.7M in common stock under its at-the-market program
- Better Therapeutics receives FDA authorization for AspyreRx
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue